Home
overview
In our 2nd conference, SMi will be looking once again to bring together the leading experts from the pharmaceutical industry to determine the progress made in realising the potential for more efficacious drug discovery and development for the treatment Chronic Obstructive Pulmonary Disease (COPD).

By the year 2020 COPD will be the third leading cause of death. COPD is the only major disease rising in mortality and prevalence in the USA. Worldwide 600 million people suffer from COPD and the global mortality is forecast to more than double over 30 years. With 50-75% of patients being undiagnosed, there is a huge, global market with enormous potential for new drug treatments.

The conference will include presentations from market leaders, specialist companies and renowned experts to talk about the latest developments in COPD research, new targets in drug discovery and drug development. Learn about the first specific drug for COPD Spiriva, discover new drug developments, hear about the latest study into the long-term impact of Seretide and assess global market opportunities and strategies.

Benefit from industry presentations by:
· Dr Chris Compton, Executive Director, Pfizer
· Prof Tim Higenbottam, Associate Director & Senior Principal Scientist, Global Clinical Science, AstraZeneca
· Prof Malcolm Johnson, Global Director, Respiratory Science, GlaxoSmithKline
· Dr Noel Snell, Global Clinical Expert, Respiratory Medicine, AstraZeneca
· Dr Heribert Staudinger, Vice President, Clinical Development Allergy, Respiratory & Clinical Immunology, Schering-Plough Research Institute
· Dr Steven Kesten, Medical Director, International Spiriva Program, Boehringer Ingelheim
· Dr Jose Carlos Gutierrez-Ramos, Vice President, Inflammation Research, Millennium
· Dr Nikolaï Khaltaev, Team Leader, Chronic Respiratory Disease Programme, World Health Organisation (WHO)

Key issues that will be addressed include:
GLOBAL TRENDS IN COPD EPIDEMIOLOGY: A view from the World Health Organisation (WHO)
NEW DRUG TARGETS FOR THE TREATMENT OF COPD: Drug discovery challenges in COPD
PRECLINICAL MODELS OF COPD: Mechanism of the disease process and ways of measuring these in animal models
CURRENT TREATMENT OPTIONS: An update on PDE4-Inhibitors, Bronchodilators, Corticosteroids and the first fixed combination treatment to gain EU approval for COPD
PANEL DISCUSSION: The challenge of advancing treatment of COPD
INDUSTRY LEADERS: Network and discuss current issues with leading industry experts

“The pace was fast and the Conference was timely. Speakers were of excellent calibre.”
Delegate, SMi's COPD Conference 2001

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Noel Snell

Dr Noel Snell, Global Clinical Expert, Respiratory Medicine, AstraZeneca

9:10 KEYNOTE ADDRESS

Dr Noel Snell

Dr Noel Snell, Global Clinical Expert, Respiratory Medicine, AstraZeneca

  • Aetiopathogenesis: smoking, pollution and genetics
  • Tissue and cell pathology
  • Natural course of the disease: can it be modified?
  • 9:40 INCREASING AWARENESS OF COPD

    Dr Michael Rudolf

    Dr Michael Rudolf, Chairman, British Thoracic Society COPD Consortium

  • Awareness of COPD and other medical conditions
  • Patients’ view of their disease and its treatment
  • 10:20 GLOBAL TRENDS IN COPD EPIDEMIOLOGY

    Dr Nikolaï Khaltaev

    Dr Nikolaï Khaltaev, Team Leader, Chronic Respiratory Disease Programme, World Health Organisation (WHO)

  • The global market
  • Prevention of COPD
  • Patient education and compliance
  • Future trends
  • 11:00 Morning Coffee

    11:20 REGULATORY CONSIDERATIONS IN THE CLINICAL DEVELOPMENT OF COPD DRUGS

    Neil Edwards

    Neil Edwards, Associate Director, Worldwide Regulatory Affairs, Parexel

  • Overview and interpretation of regulatory guidelines on development of drugs in COPD
  • How to optimally address regulatory requirements within your COPD clinical development plans
  • Validation of clinical development plans with the regulatory authorities: integration into COPD clinical development strategy
  • 12:00 NEW DRUG TARGETS FOR THE TREATMENT OF COPD

    Dr Jose Carlos Gutierrez-Ramos

    Dr Jose Carlos Gutierrez-Ramos, Vice President, Inflammation Discovery, Millennium

  • Molecules and cellular pathways
  • Targets in the RTK family
  • Targets in the chemokine receptor family
  • Targets in the NFKâ pathway
  • Drug discovery challenges in COPD
  • Animal models for pharmacology: limitations and opportunities
    Efficacy models: defence or mechanism
  • 12:40 Networking Lunch

    14:00 PRECLINICAL MODELS OF COPD

    Dr Mary Fitzgerald

    Dr Mary Fitzgerald, Director, Research & Development, Etiologics

  • Assessing current animal models
  • Assessing end points relevant to the clinic
  • Biochemical and molecular changes in animal models related to inflammation
  • Preclinical evaluation of drug candidates and the assessment of different inflammatory mechanisms
  • Protein versus small molecule approaches
  • 14:40 PDE4-INHIBITORS

    Dr Dirk Bredenbröker

    Dr Dirk Bredenbröker, Head, Clinical Research Pulmonology, Altana Pharma

  • PDE4 as an important target for the development of novel COPD therapies
  • Novel PDE4-Inhibitors under clinical development
  • Efficacy of selective PDE4-Inhibitors in COPD and asthma, exemplified by Roflumilast
  • Results of phase III clinical development of Roflumilast in COPD
  • 15:20 Afternoon Tea

    15:40 SELCIDS

    Dr Peter Schafer

    Dr Peter Schafer, Associate Director, Biology, Celgene

  • Novel PDE4-Inhibitor chemistry
  • In vitro activity
  • Animal model data
  • Comparison to competitive PDE4-Inhibitors
  • Clinical status
  • 16:20 NEW DEVELOPMENTS IN RADIONUCLIDE IMAGING FOR MEASURING DRUG DELIVERY TO THE LUNGS

    Dr Steve Newman

    Dr Steve Newman, Scientific Advisor, Pharmaceutical Profiles

  • The deposition of COPD drugs in the lungs
  • Quantification of lung deposition by gamma scintigraphy, SPECT and PET imaging
  • Improved data quantification in gamma scintigraphy and SPECT imaging
  • “Pharmacoscintigraphy”: radionuclide imaging combined with pharmacokinetics
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Prof Neil Barnes

    Prof Neil Barnes, Consultant Respiratory Physician, Barts & The London NHS Trust

    9:10 FORADIL

    Dr Stephan Stenglein

    Dr Stephan Stenglein, Medical Director, Foradil, Novartis

  • Long-term administration in the maintenance treatment of bronchoconstriction in patients with COPD
  • Stimulation of intracellular adenyl cyclase
  • Comparison of beta2-adrenergic agonist versus ipratropium bromide
  • Advantages of this treatment option
  • 9:40 CORTICOSTEROIDS

    Dr Heribert Staudinger

    Dr Heribert Staudinger, Vice President, Clinical Development Allergy, Respiratory & Clinical Immunology, Schering-Plough Research Institute

  • Reduction of oral steroid use in severe, oral-dependent asthma patients
  • Overview: the changing role of inhaled corticosteroids in COPD
  • Study endpoints in COPD
  • Potential for once daily treatment of COPD with mometasone furoate? · Effects on postbronchodilator FEV1, COPD-symptoms, quality of life and COPD exacerbations · in a study population treated with inhaled corticosteroids at randomisation · in a study population not treated with inhaled corticosteroids at randomisation
  • Combination treatment in COPD
  • 10:20 SYMBICORT

    Prof Tim Higenbottam

    Prof Tim Higenbottam, Associate Director & Senior Principal Scientist, Global Clinical Science, AstraZeneca

  • Contains corticosteroid Budesonide and rapid, long-acting bronchodilator Formoterol in a single inhaler
  • A regular treatment of COPD
  • First COPD therapy shown to reduce the frequency of acute exacerbations
  • Reduces risk of having an exacerbation
  • Advantages over placebo and traditional therapies demonstrated in two prospective randomised controlled clinical trials
  • The advantages for patients are a single inhaler with a potential wide range of doses to cope with varying clinical status
  • 11:00 Morning Coffee

    11:20 BRONCHODILATORS

    Dr Steven Kesten

    Dr Steven Kesten, Medical Director, International Spiriva Program, Boehringer Ingelheim

  • A bronchodilator for the maintenance treatment of COPD
  • Tiotropium is a long-acting inhaled antimuscarinic bronchodilator
  • Effects are due to kinetic receptor subtype selectivity for muscarinic M1 and M3 receptors
  • Tiotropium has proven more effective in clinical trials than other drug compounds
  • Patient focused outcomes and challenges
  • 12:00 ADVAIR/SERETIDE

    Prof Malcolm Johnson

    Prof Malcolm Johnson, Global Director Respiratory Science, GlaxoSmithKline

  • Multicomponent pathophysiology of COPD
  • Scientific rationale for ß2-agonists in COPD
  • Scientific rationale for inhaled steroids in COPD
  • ß2-agonist/corticosteroid combination
  • Mechanisms of action - Additive/synergistic effects - Cellular effects
  • Clinical efficacy - Lung function - Exacerbations - Health status - Morbidity/mortality data - New study in COPD (TORCH)
  • 12:40 Networking Lunch

    14:00 PANEL DISCUSSION

    Dr Steven Kesten

    Dr Steven Kesten, Medical Director, International Spiriva Program, Boehringer Ingelheim

    Dr Jose Carlos Gutierrez-Ramos

    Dr Jose Carlos Gutierrez-Ramos, Vice President, Inflammation Discovery, Millennium

    Prof Tim Higenbottam

    Prof Tim Higenbottam, Associate Director & Senior Principal Scientist, Global Clinical Science, AstraZeneca

    14:40 THE CHALLENGE OF LONG-TERM STUDY

    Dr Chris Compton

    Dr Chris Compton, Executive Director, Pfizer

  • Therapy optimisation
  • The therapeutic window
  • Reduction of side effects
  • New drug requirements
  • 15:20 PROTEASE INHIBITORS AS POTENTIAL THERAPEUTICS FOR COPD

    Dr Philip Barr

    Dr Philip Barr, Chief Scientific Officer, Arriva

  • Hereditary emphysema (HE) therapeutic strategies: a precedent for potential treatment of COPD
  • Role of alpha 1-antitrypsin (AAT) deficiency in HE
  • Neutrophil elastase vs. matrix metalloproteases in lung degeneration
  • Inhibitors of each class of protease: recombinant AAT and Ilomastat
  • Multifunctional protease inhibitors: single biological entities that inhibit multiple proteases
  • Evaluation of protease inhibitors in preclinical models for COPD
  • 16:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.